New Nanovaccine Can Improve Cellular Immunity

Cancer immunotherapies, for instance, immune checkpoint inhibition therapy, have been garnering attention in the last few years as new approaches for cancer treatment. But immune checkpoint inhibition therapy is only successful in 20%–30% of patients with cancer. Thus discovering improved drug delivery platforms to trigger anticancer cellular immunity is imperative.